Literature DB >> 26043699

SHC1 sensitizes cancer cells to the 8-Cl-cAMP treatment.

Ki Young Choi1, Young Jun Cho1, Jeong Seon Kim2, Young-Ho Ahn3, Seung Hwan Hong4.   

Abstract

8-Chloro-cyclic AMP (8-Cl-cAMP) is a cyclic AMP analog that induces growth inhibition and apoptosis in a broad spectrum of cancer cells. Previously, we found that 8-Cl-cAMP-induced growth inhibition is mediated by AMP-activated protein kinase (AMPK) as well as p38 mitogen-activated protein kinase (p38 MAPK). To identify downstream mediators of the 8-Cl-cAMP signaling, we performed co-immunoprecipitation combined with mass spectrometry using the anti-AMPK or p38 MAPK antibodies. Through this approach, SHC1 was identified as one of the binding partners of p38 MAPK. SHC1 phosphorylation was suppressed by 8-Cl-cAMP in HeLa and MCF7 cancer cells, which was mediated by its metabolites, 8-Cl-adenosine and 8-Cl-ATP; however, 8-Cl-cAMP showed no effect on SHC1 phosphorylation in normal human fibroblasts. SHC1 siRNA induced AMPK and p38 MAPK phosphorylation and growth inhibition in cancer cells, and SHC1 overexpression re-sensitized human foreskin fibroblasts to the 8-Cl-cAMP treatment. SHC1 phosphorylation was unaffected by Compound C (an AMPK inhibitor) and SB203580 (a p38 MAPK inhibitor), which suggests that SHC1 is upstream of AMPK and p38 MAPK in the 8-Cl-cAMP-stimulated signaling cascade. On the basis of these findings, we conclude that SHC1 functions as a sensor during the 8-Cl-cAMP-induced growth inhibition in SHC1-overexpressing cancer cells.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  8-Chloro-cyclic AMP; AMP-activated protein kinase; Cancer therapy; SHC1; p38 MAP kinase

Mesh:

Substances:

Year:  2015        PMID: 26043699     DOI: 10.1016/j.bbrc.2015.05.123

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

1.  Pan-Cancer Study of SHC-Adaptor Protein 1 (SHC1) as a Diagnostic, Prognostic and Immunological Biomarker in Human Cancer.

Authors:  Jianlin Chen; Gan Gao; Limin Li; Junping Ding; Xianhua Chen; Jianfei Lei; Haihua Long; Lihua Wu; Xin Long; Lian He; Yongqi Shen; Jinzhong Yang; Yonggang Lu; Yifan Sun
Journal:  Front Genet       Date:  2022-05-02       Impact factor: 4.772

2.  Yarrow supercritical extract exerts antitumoral properties by targeting lipid metabolism in pancreatic cancer.

Authors:  Lamia Mouhid; Marta Gómez de Cedrón; Elena García-Carrascosa; Guillermo Reglero; Tiziana Fornari; Ana Ramírez de Molina
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

3.  DEPDC1B is a tumor promotor in development of bladder cancer through targeting SHC1.

Authors:  Chin-Hui Lai; Kexin Xu; Jianhua Zhou; Mingrui Wang; Weiyu Zhang; Xianhui Liu; Jie Xiong; Tao Wang; Qi Wang; Huanrui Wang; Tao Xu; Hao Hu
Journal:  Cell Death Dis       Date:  2020-11-17       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.